Elena-Laura Antohi

Elena-Laura Antohi

Auto-generated profile, based on publicly available information

Elena-Laura Antohi

Emergency Institute for Cardiovascular Diseases “Prof. Dr. C.C. Iliescu”, Bucharest, Romania

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2024 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
DMDiana Cristina Matei
Diana Cristina Matei
EAElena-Laura Antohi
Elena-Laura Antohi
RIRadu Razvan Ilie
Radu Razvan Ilie
CCCelia Georgiana Ciobanu
Celia Georgiana Ciobanu
OGOliviana Dana Geavlete
Oliviana Dana Geavlete
OCOvidiu Dragomir Chioncel
Ovidiu Dragomir Chioncel

20 August 2026 in World Scientific Annual Review of Biomechanics
Verified
Journal Article
Closed access
PDF file
PKPeter L. M. Kerkhof
Peter L. M. Kerkhof
EAElena-Laura Antohi
Elena-Laura Antohi
SMSerban Mihaileanu
Serban Mihaileanu
JLJohn K-J. Li
John K-J. Li
RDRienzi A Diaz-Navarro
Rienzi A Diaz-Navarro
NHNeal Handly
Neal Handly

25 May 2026 in JRSM Cardiovascular Disease
Verified
Journal Article
Closed access
ALAntohi Laura
Antohi Laura
MSMihaileanu Serban
Mihaileanu Serban
Congestion drives symptoms and adverse outcomes in heart failure (HF), and loop diuretics remain the cornerstone of decongestion. Yet randomized trials of diuretic strategies and other acute decongestive approaches have not shown mortality benefit, while mechanistic studies demonstrate rapid neurohormonal activation after acute loop diuretic administration. In chronic HF, observational data consistently associate higher loop diuretic requirements—particularly above ∼40 mg/day furosemide equivalent or with dose escalation—with worse prognosis across HF phenotypes, though confounding by disease severity is likely. Decongestion needs vary across the HF trajectory: early guideline-directed therapy provides intrinsic decongestive effects, whereas advanced HF is marked by diuretic resistance and renal vulnerability. Preload-dependent states (notably cardiac amyloidosis and selected HFpEF phenotypes) require especially careful titration to avoid hypovolemia and low output, and robust protocol-level trial evidence is lacking. Contemporary randomized data do not demonstrate superiority of torsemide over furosemide. Small trials and systematic reviews suggest that in carefully selected, stable, non-congested patients, diuretic withdrawal or reduction can be feasible, with ∼25–35% requiring re-initiation within 1–3 months and consistent lowering of renin activity; however, clinical outcome benefit remains unproven. Overall, evidence supports maintaining euvolemia with the lowest effective diuretic dose and considering monitored deprescribing in appropriate low-risk patients.

29 April 2025 in Echocardiography
Verified
Journal Article
Closed access
PKPeter L. M. Kerkhof
Peter L. M. Kerkhof
EAElena‐Laura Antohi
Elena‐Laura Antohi
SMSerban Mihaileanu
Serban Mihaileanu